Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methodology in anti-emetic trials.

I N Olver1

  • 1Department of Medical Oncology, Royal Adelaide Hospital, Australia.

Oncology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Identifying effective anti-emetic drugs involves rigorous preclinical and clinical testing. Phase III studies are crucial for optimizing anti-emetic drug efficacy and safety, using robust methodologies to manage nausea and vomiting.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.

Internal medicine journal·2014
Same author

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2013
Same author

Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Phase II study of acivicin in patients with recurrent high grade astrocytoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2008
Same author

Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.

European journal of cancer (Oxford, England : 1990)·2007
Same author

Why we will need to learn new skills to control cancer.

Internal medicine journal·2007

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Oncology Supportive Care

Background:

  • Preclinical studies identify promising anti-emetic drug candidates.
  • Phases I and II clinical trials optimize dosing and administration routes.
  • Methodological challenges are most prominent in Phase III anti-emetic studies.

Purpose of the Study:

  • To recommend optimal methodologies for Phase III anti-emetic clinical trials.
  • To outline key factors influencing emesis that require stratification in study design.
  • To emphasize comprehensive evaluation of anti-emetic efficacy and side effects.

Main Methods:

  • Recommends a prospective, randomized, double-blind, parallel-subjects design for Phase III studies.
  • Advocates for stratification to balance key factors influencing emesis (emetic stimulus, prior chemotherapy, patient demographics, alcohol history).

Related Experiment Videos

  • Suggests using both categorical and linear-analogue scales for patient and observer evaluation.

    • Main Results:

    • Methodological rigor in Phase III trials is essential for reliable anti-emetic drug evaluation.
    • Stratification effectively balances confounding factors in randomized anti-emetic studies.
    • Comprehensive assessment includes acute, anticipatory, and delayed nausea/vomiting, alongside side effects.

    Conclusions:

    • Well-designed Phase III trials are critical for establishing anti-emetic drug efficacy and safety.
    • Careful consideration of influencing factors and side effects ensures a true assessment of anti-emetic benefits.
    • Standardized evaluation scales aid in robust data collection for anti-emetic drug assessment.